Can a simple supplement protect your heart? new trial investigates

NCT ID NCT05689710

Terminated Disease control Sponsor: Lo.Li.Pharma s.r.l Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a daily supplement containing inositol and alpha-lactalbumin can improve blood sugar, cholesterol, blood pressure, and heart health in people with metabolic syndrome who are at risk for cardiac fibrosis. Thirty participants will take the supplement for 180 days. The goal is to see if this simple approach can help control the condition and prevent heart damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inositol and alpha-lactalbumin (dietary supplement)
What this could lead to: If it works, this could point toward a simple dietary supplement to help manage metabolic syndrome and reduce the risk of heart damage.
What could go wrong: This is a small, early-stage trial with only 30 participants, and it is currently suspended. The supplement may not produce meaningful improvements, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC FIBROSIS METABOLIC SYNDROME

Contacts and locations

Locations

UOC Medicina Interna e Nefrologia P.O. AQ

L’Aquila, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.